Soligenix, Inc. (LON:0A6I)
3.270
+0.509 (18.44%)
At close: Aug 6, 2025
Soligenix Employees
As of December 31, 2024, Soligenix had 16 total employees, including 14 full-time and 2 part-time employees. The number of employees increased by 1 or 6.67% compared to the previous year.
Employees
16
Change (1Y)
1
Growth (1Y)
6.67%
Revenue / Employee
120.87 GBP
Profits / Employee
-494.74K GBP
Market Cap
6.18M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 16 | 1 | 6.67% |
Dec 31, 2023 | 15 | 0 | - |
Dec 31, 2022 | 15 | 0 | - |
Dec 31, 2021 | 15 | -3 | -16.67% |
Dec 31, 2020 | 18 | 2 | 12.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
HSBC Holdings | 211,304 |
Shell | 96,000 |
Unilever | 115,964 |
British American Tobacco p.l.c. | 48,989 |
Rolls-Royce Holdings | 42,400 |
Rio Tinto Group | 60,000 |
BP p.l.c. | 100,500 |
Soligenix News
- 5 days ago - NetworkNewsAudio Announces Audio Press Release (APR) on Promising First-Line Therapy for Rare Skin Cancer - GlobeNewsWire
- 13 days ago - Crude Oil Falls 1%; Meta Earnings Top Views - Benzinga
- 13 days ago - Nasdaq Surges Over 1%; Microsoft Posts Upbeat Earnings - Benzinga
- 13 days ago - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease - Benzinga
- 13 days ago - Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease - PRNewsWire
- 5 weeks ago - Soligenix Corporate Update Letter - Key Highlights and Upcoming Milestones - PRNewsWire
- 6 weeks ago - Soligenix Announces Synthetic Hypericin Successfully Manufactured at Sterling Pharma Solutions - PRNewsWire
- 2 months ago - Soligenix Highlights Dr. Ellen Kim's Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials - GlobeNewsWire